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Binding of myeloperoxidase to 
the extracellular matrix of smooth 
muscle cells and subsequent matrix 
modification
Huan cai, christine Y. chuang, clare L. Hawkins & Michael J. Davies*
The extracellular matrix (ECM) of tissues is susceptible to modification by inflammation-associated 
oxidants. Considerable data support a role for hypochlorous acid (HOCl), generated by the leukocyte-
derived heme-protein myeloperoxidase (MPO) in these changes. HOCl can modify isolated ECM 
proteins and cell-derived matrix, with this resulting in decreased cell adhesion, modulated proliferation 
and gene expression, and phenotypic changes. Whether this arises from free HOCl, or via site-specific 
reactions is unresolved. Here we examine the mechanisms of MPO-mediated changes to human 
coronary smooth muscle cell ECM. MPO is shown to co-localize with matrix fibronectin as detected by 
confocal microscopy, and bound active MPO can initiate ECM modification, as detected by decreased 
antibody recognition of fibronectin, versican and type IV collagen, and formation of protein carbonyls 
and HOCl-mediated damage. These changes are recapitulated by a glucose/glucose oxidase/MPO 
system where low continuous fluxes of H2o2 are generated. HOCl-induced modifications enhance 
Mpo binding to ecM proteins as detected by eLiSA and Mpo activity measurements. these data 
demonstrate that MPO-generated HOCl induces ECM modification by interacting with ECM proteins in 
a site-specific manner, and generates alterations that increase MPO adhesion. This is proposed to give 
rise to an increasing cycle of alterations that contribute to tissue damage.
The extracellular matrix (ECM) is essential for the homeostasis of tissues. In the case of the artery wall, the vas-
cular basement membrane plays a key role in supporting and determining endothelial and smooth muscle cell 
survival and function1. This ECM forms a specialized and distinct microenvironment, with the biomacromole-
cules (e.g., collagens, laminins, fibronectin, perlecan, versican, elastin, nidogen, syndecans) that comprise this 
material, and a myriad of associated materials (e.g., cytokines, growth factors) dictating the shape and function 
of the artery wall, and the nature and behavior of the associated vascular cells2. Due to the lower turnover rate of 
many ECM materials (cf. estimated half-lives of 60–70 days and 74 years for arterial collagen and elastin, respec-
tively3,4), and the low levels of antioxidant defense systems in extracellular environments5, ECM components 
and proteins in biological fluids appear to be particularly susceptible to oxidant damage. These factors result in a 
gradual accumulation of damage in the ECM with both aging and disease, including within the artery wall during 
the development of atherosclerosis (reviewed2,6). At least some of this damage appears to arise via the formation 
of oxidants generated by the leukocyte-derived heme enzyme myeloperoxidase (MPO)7.
Alterations to the structure and properties of ECM has been associated with the progression of atherosclerosis8. 
Previous studies have shown that approximately 70% of the oxidation products detected on proteins extracted 
from human atherosclerotic lesions are present on ECM proteins7, consistent with the high abundance of ECM 
in this tissue (estimated as 30–60%9). Multiple different oxidized protein side chains have been detected on lesion 
proteins at higher levels than in normal healthy tissue, with these including hydroxylated, cross-linked, nitrated 
and chlorinated species. Some of these products are associated with the presence and activity of particular oxidant 
generating systems, including redox-active metal ions (hydroxylated products)10–12, reactive nitrogen species (e.g. 
peroxynitrous acid, as evidenced by the presence of 3-nitrotyrosine and 6-nitrotryptophan)13–16, and reactive 
chlorine species such as hypochlorous acid (HOCl, generated by MPO) which generate 3-chlorotyrosine and 
other chlorinated products17–22. The relative roles of these oxidants, and the events that give rise to the observed 
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damage remain to be fully established, though it is known that both reactive nitrogen species and HOCl can be 
generated by MPO (reviewed23).
Considerable evidence supports a role for MPO in the pathogenesis of atherosclerosis. MPO mRNA, pro-
tein and enzymatic activity are present in lesions24, elevated levels of HOCl-damaged proteins are present18,25, 
and increased concentrations of the HOCl-generated biomarkers, 3-chlorotyrosine and 5-chlorouracil have been 
reported17,21. There is a strong association between the levels of HOCl-damaged proteins and the severity of 
disease (as judged by intimal-medial thickness)18,19, and the plasma levels of MPO have been shown, in multiple 
epidemiological and clinical studies, to be both diagnostic and prognostic of poor cardiovascular (and other 
disease) outcomes26–28.
MPO is released from intracellular storage granules of activated neutrophils, monocytes and some tissue mac-
rophages, and shows a high affinity for both ECM proteins and negatively-charged glycosaminoglycan (GAG) 
chains due to the high abundance of (positively-charged) Lys and Arg residues on the protein surface29–31. These 
observations suggest that the HOCl formation by MPO/H2O2/Cl− may occur in a localized and site-specific man-
ner. This is consistent with binding of (highly-cationic) MPO to ECM materials such as GAG chains30,32 including 
those of the glycocalyx33, proteoglycans such as perlecan31, and lipoproteins such as high- and low-density lipo-
proteins (HDL and LDL, respectively)17,22,34. MPO protein has been reported to be particularly localized to the 
shoulder regions of lesions, which are especially prone to rupture and thrombus formation35,36, and high numbers 
of MPO-expressing cells have been reported at such sites37–39.
In recent studies with isolated human plasma fibronectin exposed to HOCl or a MPO/H2O2/Cl− system, 
differences were detected in both the extent and sites of modification between these two systems40. One potential 
explanation for these differences is site-specific formation of HOCl as a result of MPO binding to the protein40. As 
a consequence, we have examined the underlying mechanism(s) by which MPO-derived HOCl induces oxidation 
of human coronary artery smooth muscle cell (HCASMC) ECM, by examining the hypothesis that MPO binds to 
fibronectin and that this gives rise to site-specific oxidant formation and localized ECM damage.
Results
Decellularization of primary HCASMC cultures using sodium deoxycholate and immunolocali-
zation of ECM components. Previous studies have commonly used NH4OH to remove cells from cultures 
to give isolated ECM preparations41. This method was used in initial experiments, but such treatment results in 
a loss of some ECM materials as judged by a decreased detection of fibronectin (determined by immunofluores-
cence using an anti-fibronectin pAb) in NH4OH-treated samples compared to controls (Supplementary Fig. 1).
Recent studies have employed sodium deoxycholate (DOC, 1%) to decellularize murine tissues, with mini-
mal reported damage to native ECM components, allowing high-resolution imaging and proteomic analyses42. 
Consequently, this treatment was examined as a potential method for obtaining native ECM from cell cultures. 
HCASMCs were cultured on chamber culture slides for 1 week to produce HCASMC-ECM. The slides were then 
examined either as intact structures, or incubated with 1% DOC to remove cells. Double immunofluorescence 
staining using primary antibodies against cell-derived fibronectin-extra domain A (EDA) (mAb 3E2) and type 
IV collagen (pAb) was then employed to examine both the presence and levels of ECM materials. The intact 
HCASMC-containing wells stained positive for type IV collagen both intracellularly and extracellularly (Fig. 1, 
Figure 1. Immunolocalization of native and decellularized ECM components synthesized by primary 
HCASMCs. HCASMCs were cultured for 1 week to allow the synthesis and assembly of native ECM, then 
either left untreated (control) or treated with 1% sodium deoxycholate (DOC; bottom panel) to lyse and 
solubilize the attached cells. Matrix proteins were detected via double immunofluorescence staining using 
primary antibodies against type IV collagen (pAb) and the cell-derived fibronectin EDA region (FN-3E2). 
Alexa Fluor 488-conjugated anti-rabbit secondary antibody (green) and an Alexa Fluor 594-conjugated anti-
mouse secondary antibody (red) were used to visualize matrix protein-primary antibody complexes, with nuclei 
counterstained using DAPI (blue). Representative images from n = 3 independent experiments are shown. Scale 
bars: 50 μm.
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top row; green fluorescence), cell-derived fibronectin localized extracellularly as fibre-like structures (Fig. 1, top 
row; red fluorescence), and cell nuclei (Fig. 1, top row; blue fluorescence from DAPI). Control samples showed no 
fluorescence indicating a high specificity of these antibodies (Supplementary Fig. 2). Examination of DOC-treated 
wells showed the presence of extracellular type IV collagen as fibre-like structures and cell-derived fibronectin but 
no blue fluorescence from DAPI (Fig. 1, bottom row). These data indicate that DOC treatment is an efficient and 
gentle decellularizing agent for monolayers of HCASMCs in vitro. Versican, another key matrix component, was 
also detected in the DOC treated cultures by double immunofluorescence staining using an anti-fibronectin pAb 
and anti-versican mAb (12C5, which recognizes the hyaluronate-binding G1 domain) (Supplementary Fig. 3).
MPO binds to matrix proteins in HCASMC-ECM. As MPO binds with high affinity to some biological 
materials (see Introduction) we hypothesized that MPO may bind to and colocalize with HCASMC-ECM mate-
rials and induce selective ECM damage. Consequently, we investigated the affinity of MPO for matrix proteins 
present in decellularized HCASMC-ECM. HCASMC-ECM samples were prepared using DOC, blocked with 
BSA, then incubated with MPO (20 nM) for 30 min at 37 °C. After washing to remove non-adherent materials, the 
presence of fibronectin and MPO was examined via double immunofluorescence using an anti-fibronectin pAb 
and an anti-MPO mAb (2C7). Fibronectin was detected within the decellularized HCASMC-ECM as fibre-like 
structures, with the fluorescence from MPO strongly co-localized with this material, as evidenced by the merged 
images (Fig. 2; see also Supplementary Fig. 2).
Further evidence for a direct MPO-FN interaction was obtained by immunoprecipitation of an MPO-FN 
complex using an anti-MPO mAb (2C7). The material pulled-down by mAb 2C7 showed positive staining at the 
expected mass of FN monomers, after separation of the proteins on SDS-PAGE and probing with an anti-FN pAb 
in immunoblotting experiments (Fig. 3).
Modification of HCASMC-ECM proteins by MPO/H2o2/Cl−. We have shown previously that 
MPO-derived HOCl modifies HCASMC-ECM preparations decellularized using NH4OH43. Here, we inves-
tigated the extent of HOCl-induced modification generated on (more intact) DOC-decellularized ECM by a 
bound MPO/H2O2/Cl− system, with alterations to the ECM detected by ELISA using primary antibodies that 
recognize HCASMC-ECM proteins. Native HCASMC-ECM was prepared using DOC (as above) and exposed 
to MPO (20 nM), Cl− (200 mM) and varying concentrations of H2O2 (5–100 μM). This system gives near quanti-
tative conversion of H2O2 to HOCl40,43. Exposure of the decellularized HCASMC-ECM to the MPO system with 
100 μM H2O2 resulted in significant losses in epitope recognition by both the anti-fibronectin pAb (Fig. 4A) and 
anti-versican mAb (12C5), with ≥20 μM or higher H2O2 (Fig. 4B). With the type IV collagen pAb, a significant 
increase in epitope recognition was detected with 10 μM H2O2 (Fig. 4C), possibly as a result of increased exposure 
of cryptic epitopes as a result of modification to other ECM components. However, with 100 μM H2O2, a signif-
icant decrease in epitope recognition by this antibody was apparent. Concurrently, a significant increase in the 
presence of HOCl-generated epitopes was detected, as evidenced by recognition by mAb 2D10G9 (which recog-
nises HOCl-modified proteins), with this being dose-dependent, and significant with ≥20 μM H2O2 (Fig. 4D).
Increased recognition of ECM materials by the 2D10G9 mAb upon exposure to MPO/H2O2/Cl− system was 
also examined using immunofluorescence staining. The fibronectin pAb, and mAb 2D10G9 were used to detect 
fibronectin and HOCl-generated epitopes in the decellularized HCASMC-ECM exposed to the MPO system, in 
Figure 2. Colocalization of fibronectin and MPO in decellularized native HCASMC-ECM. Decellularized 
HCASMC-ECM was exposed to 20 nM of MPO at 37 °C for 30 min. Fibronectin and MPO were detected by 
primary antibodies: (left column) fibronectin pAb (A17), (middle column) anti-MPO 2C7 mAb. Merged 
images are shown in the right column. An Alexa Fluor 488-conjugated anti-rabbit secondary antibody (green) 
and an Alexa Fluor 594-conjugated anti-mouse secondary antibody (red) were used to visualize matrix 
protein-primary antibody complexes, by confocal microscopy. Representative images from n = 3 independent 
experiments are shown. Scale bars: 50 μm.
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experiments with 20–100 μM H2O2. These treatments resulted in significant damage to the matrix structure, as 
evidenced by fragmentation and loss of the fibronectin fibres with increasing H2O2 concentrations (Fig. 5, top 
row). Concurrent with these changes, increased recognition of matrix materials was detected with mAb 2D10G9 
in a H2O2-dependent manner (Fig. 5, middle row). This staining colocalized with the fibronectin fibres (Fig. 5, 
bottom row). Similar data were obtained in immunofluorescence studies using a type IV collagen pAb and mAb 
2D10G9, with a marked loss of recognition by the collagen antibody detected with both 20 and 100 μM H2O2 
(Fig. 6, top row) and detection of material recognized by mAb 2D10G9 (Fig. 6, middle row), and colocalization 
of this fluorescence (Fig. 6, bottom row).
Increased affinity of MPO for oxidized HCASMC-ECM. The above data are consistent with binding of 
MPO to HCASMC-ECM, with the MPO remaining catalytically-active and able to induce modifications to the 
ECM. However, it is unclear whether oxidized ECM also has this capacity. We therefore investigated the affinity of 
MPO for native, or HOCl-exposed HCASMC-ECM, via ELISA. Concurrently, the activity of matrix-bound MPO 
was examined in a quantitative manner using the TMB assay which relies on the conversion of taurine to taurine 
chloramine by HOCl, and subsequent assay of this chloramine44.
Reagent HOCl modified the decellularized HCASMC-ECM, with significantly increased mAb 2D10G9 rec-
ognition detected via ELISA, with this increasing in a dose-dependent manner; this increase was significant at 
≥20 μM HOCl (Fig. 7A, black bars). Interestingly, an increased absorbance at 405 nm, arising from recognition 
by the MPO mAb, was also observed for the samples treated with ≥20 μM HOCl, and in a dose-dependent 
manner, consistent with MPO binding to the modified ECM, and having a higher affinity for the modified, 
compared to native, HCASMC-ECM (Fig. 7A, white bars). To confirm the increased binding of MPO to the 
oxidized ECM, the enzymatic activity of the matrix-bound MPO was quantified using the TMB assay, with a 
fixed concentration of H2O2 (50 μM) added to the MPO adherent on the ECM in the presence of taurine to trap 
the resulting HOCl. A significantly increased absorbance at 645 nm was observed for MPO bound to the ECM 
treated with 20 μM HOCl, when compared to the MPO bound to native ECM, consistent with an increased 
concentration of active MPO bound to the oxidized, compared to native, HCASMC-ECM (Fig. 7B). The yield 
of taurine chloramine quantified using TMB reached an apparent plateau when the initial ECM was treated with 
higher concentrations of HOCl, suggesting that the H2O2 added to the system can be depleted by the activity 
of the bound MPO.
The potential role of ECM oxidation products in the increased affinity of MPO for the oxidized matrix, 
was examined by quantifying the level of carbonyls formed on the HCASMC-ECM treated with differ-
ent concentrations of reagent HOCl (10–200 μM). The carbonyl yields were measured by derivatization with 
Figure 3. Immunoprecipitation of fibronectin using an anti-MPO mAb. Evidence for a direct MPO-FN 
interaction was investigated by immunoprecipitation using an anti-MPO mAb (2C7; 2 μg) bound to Protein 
A/G magnetic beads (Pierce, IL, USA). MPO (20 nM) was pre-incubated with FN (20 nM) to allow potential 
MPO-FN complex formation prior to incubation with anti-MPO mAb bound to magnetic beads. MPO-FN 
protein complexes immunoprecipitated with the anti-MPO mAb magnetic beads were separated on 3–8% 
tris-acetate SDS-PAGE gels and subsequently immunoblotted for the presence of FN monomers (filled arrow) 
using an anti-FN pAb and imaged by chemiluminescence. Lanes 1–4 were obtained from a blot with a long 
chemiluminescence accumulation time, carried out to confirm the absence of any recognized material in the 
controls represented by lanes 1 and 2. The detection of weak bands in lane 3 when compared to lane 4 indicates 
some non-specific binding of the FN-MPO complex to the beads alone. Lanes 5 and 6, are samples from another 
experiment, which used a shorter chemiluminescence detection time, to show the differences in staining 
intensity between the samples with and without mAb 2C7 against MPO. Representative images from n = 3 
independent experiments are shown.
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2,4-dinitrophenylhydrazine (DNPH) and detection of the resulting hydrazone products using an anti-DNPH 
antibody (Fig. 8). Treatment with HOCl resulted in a marked increase in HCASMC-ECM-derived carbonyl levels 
even at the lowest oxidant levels tested (10 μM), though the levels of these products did not increase in a linear 
manner with increasing HOCl concentrations, consistent with further reaction of these (reactive) products. Such 
behavior is consistent with previous reports45,46.
MPO-induced HCASMC-ECM oxidation is dependent on the flux of H2o2. The data presented 
above indicate that a MPO-mediated oxidation system can modify decellularized HCASMC-ECM, as detected 
by ELISA or immunofluorescence staining with mAb 2D10G9. This occurs in a concentration-dependent man-
ner with increasing concentrations of H2O2 ≥ 20 μM. Decreased ECM epitope recognition was also detected by 
antibodies raised against fibronectin, type IV collagen and versican mAb (12C5). However, the H2O2 used in 
these experiments was added as a bolus dose rather than continuously, with the latter more likely to reflect the 
biological situation. The overall concentrations are however close to those reported as a steady-state level (cf. 
reports of H2O2 concentrations in plasma of 1–10 μM47). As a consequence, we examined modification of the 
HCASMC-ECM by associated MPO where the H2O2 was generated in situ using a glucose/glucose oxidase (GO) 
system, that generates H2O2 over a long time period, with potential damage to the HCASMC-ECM detected using 
immunofluorescence staining and ELISA, as described above.
The GO/glucose/MPO/Cl− system generated oxidative damage to HCASMC-ECM in a GO concentration- 
dependent manner as determined by ELISA, with GO levels ≥100 mU mL−1 giving a statistically-significant 
increase in damage (Fig. 9A, black bars) relative to the corresponding controls that did not contain MPO 
(Fig. 9A, white bars). Exposure of HCASMC-ECM to a fixed concentration of the oxidant system (400 mU 
mL−1 GO, 5 mM glucose, 20 nM MPO, 200 mM Cl−) for increasing incubation times gave a time-dependent 
increase in HCASMC-ECM damage, as evidenced by increasing ELISA signals arising from mAb 2D10G9, for 
exposure times ≥2 h (Fig. 9B, black bars). In the absence of MPO this increase in absorbance was not detected 
(Fig. 9B, white bars). Immunofluorescence staining using the pAb against fibronectin, and mAb 2D10G9 against 
HOCl-mediated damage, supported this conclusion. Thus, significant green fluorescence arising from the pres-
ence of fibronectin was observed in each group (Fig. 9C, left column), whereas red fluorescence arising from the 
presence of HOCl-modified epitopes was absent in the controls, but increased in extent with longer incubation 
times (Fig. 9C, middle column), such that a marked increase in fluorescence was detected after 20 h. The fluores-
cence from these two antibodies was strongly colocalized (Fig. 9C, right column).
Figure 4. Effects of MPO-H2O2-Cl− system on epitope recognition of primary antibodies against matrix 
proteins in native HCASMC-ECM. Decellularized HCASMC-ECM was left untreated (control; 0 μM) or treated 
with an MPO-H2O2-Cl− system (20 nM MPO, 5–100 μM H2O2, 200 mM Cl−). Loss of recognition of specific 
ECM components were detected by primary antibodies against: (A) fibronectin (pAb), (B) versican (12C5 
mAb), (C) type IV collagen (pAb), and (D) the formation of HOCl-generated epitopes (mAb 2D10G9). Data are 
presented as means ± SEM from n = 3 independent experiments, and are expressed as a % of the control data 
(fibronectin, versican and type IV collagen), or the % of the maximal ELISA signal detected with mAb 2D10G9, 
with statistical analysis carried out using one-way ANOVA with Tukey’s post-hoc tests. * indicates statistical 
significance from the control (0 μM added H2O2) at the p < 0.05 level, and ** the p < 0.01 level.
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Discussion
It is well established that elevated levels of oxidized DNA, RNA, proteins and lipids are present in atherosclerotic 
lesions, but the nature of the oxidants that generate these changes and the specific pathways involved remain to be 
fully elucidated48. We have reported that exposure of HCASMC-ECM to either reagent or MPO-derived HOCl 
can give rise to oxidative modifications of the HCASMC-ECM and its components, and that these modified 
materials affect the behavior of HCASMCs, including loss of adhesion, accelerated proliferation and modulated 
gene expression43. While MPO is vital for innate immunity49, aberrant expression of MPO and subsequent oxi-
dant production have been implicated in many inflammatory diseases, including atherosclerosis (ref. 36, see also 
Introduction).
Here we have examined, at an in vitro level, how MPO modifies matrix proteins. MPO is shown to bind to 
ECM proteins, and to retain its catalytic activity, resulting in the generation of HOCl in the presence of Cl− and 
H2O2, resulting in modifications to HCASMC-ECM materials. These modifications are localized to the vicinity of 
MPO, though the exact targets and specific binding sites require confirmation. These changes were recapitulated 
by exposure of HCASMC-ECM to a GO/glucose/MPO/Cl− system, as evidenced by increased antibody recogni-
tion of HOCl-mediated damage (via ELISA and immunofluorescence assay) by 2D10G9 mAb. This occurred in a 
time-dependent manner, with increasing levels detected with higher fluxes of H2O2 as judged by a dependence on 
the GO concentration. A previous study has also reported direct modification of isolated fibronectin by H2O2, but 
this was dependent on trace metal ions which generate hydroxyl radicals (HO.) and required high levels of H2O250. 
Whether such HO. mediated damage is of importance in vivo remains to be established, as redox active metal ions 
would be expected to be tightly-bound to endogenous metal-ion binding proteins.
Interestingly, the extent of MPO-binding appears to be dependent on the level of HOCl-induced modifica-
tions, with greater binding apparent (when compared to the non-treated HCASMC-ECM) after pre-treatment of 
the ECM with HOCl, as indicated by the ELISA data where increased epitope recognition of MPO by anti-MPO 
mAb (2C7) was observed with HOCl-pre-treated HCASMC-ECM. Our data are therefore consistent with a new 
paradigm in which MPO participates in the development and progression of atherosclerosis through the genera-
tion of damage to matrix proteins, which then bind increasing concentrations of MPO as a result of an enhanced 
affinity of the enzyme for modified ECM. This bound MPO has been shown to retain a high level of enzymatic 
activity. This would result in a vicious cycle of increasing ECM alteration by MPO-derived oxidants, greater MPO 
binding to the damaged materials, and increased site-dependent oxidant formation. This has been associated 
with aberrant cell behavior including decreased cell adhesion, modulated proliferation, phenotypic switching 
of smooth muscle cells, altered gene expression, release of pro-inflammatory species, and matrix remodeling43.
The cultured primary HCASMC employed in this study produce abundant ECM materials in vitro, which 
in turn support the adhesion and survival of adherent cells. Immunofluorescence staining shows that different 
Figure 5. Effects of MPO-H2O2-Cl− system on integrity of native HCASMC-ECM proteins. Decellularized 
native ECM was exposed to MPO-H2O2-Cl− system (20 nM MPO, 0–100 μM H2O2, 200 mM Cl−) at 
37 °C for 2 h. The presence of HOCl-induced modifications to matrix proteins were detected via double 
immunofluorescence staining using fibronectin pAb (green) and mAb 2D10G9 (red), respectively. An Alexa 
Fluor 488-conjugated anti-rabbit secondary antibody (green, top row) and an Alexa Fluor 594-conjugated 
anti-mouse secondary antibody (red, middle row) were used to visualize matrix protein-primary antibody 
complexes. Merged images are shown in the bottom row. Representative images from n = 3 independent 
experiments are shown. Scale bars: 50 μm.
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matrix proteins, including fibronectin, type IV collagen and versican, appear as fibre-like structures, indicating 
that these ECM proteins interact with each other to form a 3-dimensional scaffold to which the HCASMCs adhere 
and proliferate. We have previously prepared decellularized HCASMC-ECM using NH4OH43, which allows effi-
cient removal of adherent cells, but this protocol has been shown here to result in loss and disruption of the ECM 
materials and structure. However, DOC, which has been successfully used to decellularize other tissues42, allows 
the harvesting of matrix components laid down by HCASMC, which appear to be structurally-intact. This intact 
decellularized HCASMC-ECM provides a better model to investigate matrix-cell and matrix-MPO interactions 
in vitro.
The current data indicate that MPO binds to matrix proteins, as evidenced by the colocalization of fibronectin 
and MPO detected via double immunofluorescence staining, confirming the data of Kubala et al.30. This suggests 
that MPO-induced damage to matrix proteins may be dependent on the specificity of binding to matrix proteins 
or sites. This is supported by the immunofluorescence staining, which shows that the HOCl-oxidized epitopes 
were primarily detected in the same regions as MPO binding to the ECM materials.
The mechanism(s) that underlie the increased MPO binding to HOCl-modified ECM have not been deter-
mined in detail, but the results obtained, and literature data provide a potential explanation. It is known that 
HOCl preferentially targets Cys, Met, cystine, His, α-amino, Trp, Lys and Tyr residues, in order of decreasing 
reactivity51,52. The resulting products have been elucidated53. For some residues, reaction results in conversion of 
a neutral species to a negatively-charged product (e.g. conversion of Cys and cystine to oxy acids, oxidation of His 
to give the carboxylic-acid containing residue Asp)53. Reaction at other residues (e.g. at His, α-amino and Lys) 
converts positively-charged (protonated nitrogen) groups to neutral species (e.g. Asn from His, carbonyls and 
nitriles from α-amino and Lys species)53. This increased negative charge, and loss of positive charge, may result in 
increased binding of (highly-positively charged) MPO via electrostatic interactions. Covalent bonding may also 
contribute, as elevated levels of carbonyls (a known product of amine (Lys) oxidation by HOCl45), were detected 
on HOCl-treated HCASMC-ECM. Carbonyls can undergo Schiff base reactions with Lys and Arg residues, that 
are present in abundance in the MPO structure (55 Arg and 14 Lys in the mature protein, ~12% abundance: 
UniProt entry: P05164). Such reactions have been reported previously to contribute to inter-molecular protein 
cross-linking (e.g.54).
The MPO bound to oxidized HCASMC-ECM is enzymatically active, as shown by the detection and quan-
tification of taurine-derived chloramines. Whether this bound material is more or less active than free MPO, is 
unclear and difficult to assess due to difficulties in quantifying the amount of MPO bound to the ECM. Recent 
mass spectrometry data suggests that some ECM proteins are less extensively modified by the MPO system rela-
tive to the same concentration of reagent HOCl (e.g. fibronectin40), and others such as laminins more modified55, 
Figure 6. Effects of MPO-H2O2-Cl− system on integrity of native Type IV collagen. Decellularized native 
ECM was exposed to MPO-H2O2-Cl− system (20 nM MPO, 0–100 μM H2O2, 200 mM Cl−) at 37 °C for 2 h. The 
presence of HOCl-induced modifications to matrix proteins were detected via double immunofluorescence 
staining using a collagen IV pAb and mAb 2D10G9, respectively. An Alexa Fluor 488-conjugated anti-rabbit 
secondary antibody (green, top row) and an Alexa Fluor 594-conjugated anti-mouse secondary antibody (red, 
middle row) were used to visualize matrix protein-primary antibody complexes. Merged images are shown in 
the bottom row. Representative images from n = 3 independent experiments are shown. Scale bars: 50 μm.
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as judged by both the number, and level of modifications. These differences have been rationalized in terms of 
MPO binding to these species and possible alterations in activity. In HCASMC-EMC both fibronectin and lamin-
ins are present, therefore it is not possible to decipher the which effect may be more important. Although the 
nature of the specific MPO binding sites remain to be elucidated, it is nonetheless clear that higher levels of MPO 
are bound to the ECM after prior matrix oxidation.
Figure 7. Increased affinity of MPO for oxidized HCASMC-ECM. (A) Decellularized HCASMC-ECM was 
prepared and exposed to buffer or 5–100 μM HOCl at 37 °C for 2 h, washed, and then incubated with 10 nM of 
MPO at 37 °C for 30 min. The samples were then washed to remove non-adherent material, before analysis of 
matrix-bound MPO and HOCl-mediated damage via ELISA using MPO mAb (2C7) and 2D10G9, respectively. 
In (B), matrix-bound MPO (prepared as described above) was incubated with 50 μM H2O2, 200 mM Cl− and 
10 mM taurine (to trap HOCl) at 37 °C for 2 h. The resulting taurine chloramines were assayed using TMB (see 
Materials and methods) with the absorbance recorded at 645 nm. Data from triplicate determinations (n = 3 
independent experiments) were analyzed by one-way ANOVA with Tukey’s post-hoc test. * indicates statistical 
significance from the control (0 μM added HOCl) at the p < 0.05 level, and ** at the p < 0.01 level.
Figure 8. Formation of carbonyl groups on decellularized HCASMC-ECM by reagent HOCl. Decellularized 
HCASMC-ECM was prepared then either left untreated (control; 0 μM) or treated with reagent HOCl 
(0–200 μM) for 2 h at 37 °C before determination of the protein carbonyl content after derivatization with 
2,4-dinitrophenylhydrazine, and subsequent recognition of the corresponding hydrazone by a commercial 
antibody with ABTS as the chromophore. Data from n = 3 independent experiments are expressed as 
mean ± SEM of the absorbance values at 405 nm. Statistical analysis was carried out using one-way ANOVA 
with Tukey’s post-hoc tests. ** indicates significance at the p < 0.01 level.
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These data imply that in vivo, increased inflammation, enhanced neutrophil/monocyte/macrophage activa-
tion and release of MPO, may result in increasing levels of MPO being associated with the ECM, which could 
promote further matrix modification. This positive feedback loop could potentially increase the rate of disease 
development and result in the accumulation of oxidized ECM proteins. This is consistent with the detection of 
Figure 9. MPO-induced HCASMC-ECM oxidation is dependent on the flux of H2O2. HCASMC-ECM was 
incubated with (A) GO-MPO system (0–400 mU mL−1 glucose oxidase, 5 mM glucose, 20 nM MPO) for 20 h, 
or (B) GO-MPO system (400 mU mL−1 glucose oxidase, 5 mM glucose, 20 nM MPO) for 0–20 h. The extent of 
ECM damage was then quantified using the mAb 2D10G9 in an ELISA assay. (C) HCASMC-ECM was exposed 
to a GO-MPO system (400 mU mL−1 glucose oxidase, 5 mM glucose, 20 nM MPO) for 0–20 h, with parent ECM 
fibronectin and oxidative modifications to the HCASMC-ECM detected using immunofluorescence. Fibronectin 
and HOCl-induced modifications were detected using fibronectin pAb (left column) and mAb 2D10G9 (middle 
column), the corresponding images are merged in the right column. An Alexa Fluor 488-conjugated anti-rabbit 
secondary antibody (green) and an Alexa Fluor 594-conjugated anti-mouse secondary antibody (red) were used 
to visualize matrix protein-primary antibody complexes. In (A and B), absorbance data at 405 nm are presented 
as means ± SEM from n = 3 independent experiments. * Indicates statistical significance from the control (0 μM 
added GO or time zero data) at the p < 0.05 level, and ** at the p < 0.01 level by ANOVA with Tukey’s post-hoc 
tests. In (C), representative images from n = 3 independent experiments are shown. Scale bars: 30 μm.
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elevated levels of oxidized materials in advanced human atherosclerotic lesions compared to healthy tissues, and 
an accumulation with age and disease7. The low turnover rate and poor antioxidant activity of the ECM5 would 
also be expected to favor such accumulation.
Overall our data demonstrates, at an in vitro level, a mechanism by which MPO induces and drives increasing 
modification of the ECM (Fig. 10). MPO appears to have a high affinity for at least some matrix proteins, with 
the matrix-bound MPO able to catalyse HOCl generation, and oxidative modifications to the ECM; this appears 
to be localized at, or near, sites of MPO-binding. These modifications then enhance further binding of MPO and 
damage, with this accumulating in a time- and HOCl flux-dependent manner. These data increase our under-
standing of the mechanisms that underlie MPO-matrix interactions and MPO-induced matrix oxidation, and 
provide potential insights into the prevention or amelioration of inflammation-associated diseases, including 
atherosclerosis.
Materials and Methods
Reagents. All solutions were prepared using nanopure Milli-Q H2O (Millipore). H2O2 and HOCl concentra-
tions were quantified spectrophotometrically (H2O2, ε240 nm 43.6 M−1 cm−1 56; HOCl (at pH 12), ε292 nm 350 M−1 
cm−1 57). pH control of reaction mixtures was achieved by using 0.1 M sodium phosphate buffer, pH 7.4. All 
chemicals were obtained from Sigma (Sigma-Aldrich) unless otherwise stated. Human polymorphonuclear leu-
kocyte-derived MPO was purchased from Planta Natural Products (Vienna, Austria).
cell culture of HcASMc. Commercially-sourced primary HCASMCs (Cell Applications, San Diego, USA; 
donor number #1596, Caucasian, male, age 53) were cultured (up to passage 5) in T-75 tissue culture flasks under 
20% O2 and 5% CO2, at 37 °C in a humidified incubator. Cells were seeded at an initial density of 5 × 105 cells in 
15 mL growth medium (Cell Applications, USA; Smooth Muscle Cell Growth Medium, product number #311-
500), with the media replaced three times per week.
Immunofluorescence staining of ECM materials and modification products. HCASMCs (passage 
4) were seeded onto eight-well chamber glass culture slides (Becton Dickinson) at an initial density of 2 × 104 
cells per well and cultured for 1 week to allow ECM synthesis. HCASMCs on the slides were treated twice with or 
without 1% (w/v) sodium deoxycholate (DOC) for 10 min at 21 °C with gentle rocking, followed by 5 washes with 
PBS. The slides were then fixed with 4% (v/v) formaldehyde at 37 °C for 15 min, then permeabilized using 0.5% 
(v/v) Triton X-100 in PBS on ice for 5 min. The slides were blocked with 1% (v/v) BSA in PBS at 21 °C for 1 h and 
then incubated with primary antibodies at 4 °C overnight. The primary antibodies were used at the following dilu-
tions: anti-cell derived fibronectin EDA epitope (Sigma, 3E2 mAb; 1:1000), anti-fibronectin pAb (Abcam, ab2413; 
1:1000), anti-type IV collagen (Abcam, ab6586; 1:1000), anti-MPO (Abcam, 2C7 mAb; 1:1000), anti-versican 
G1 domain (Developmental Studies Hybridoma Bank, Univ. of Iowa, USA, 12C5 mAb; 1:1000) and anti-HOCl 
generated epitopes (kindly provided by Prof. Ernst Malle, Medical University of Graz, Austria; 2D10G9 mAb, 
1:200). The slides were rinsed twice with PBS then incubated with anti-mouse IgG conjugated with Alexa Fluor 
488 antibody and anti-rabbit IgG conjugated with Alexa Fluor 594 antibody (both Molecular Probes; 1:1000 in 1% 
(v/v) BSA in PBS) at 21 °C for 1 h. The slides were rinsed again with PBS and then counterstained with 1 μg mL−1 
DAPI (4′,6-diamidino-2-phenylindole, Molecular Probes) in PBS in the dark at 4 °C for 10 min, followed by three 
rinses with PBS, before being air dried and the cover slips added, with imaging using a fluorescence microscopy 
(Olympus, Japan) equipped with cellSense Entry v1.5 software.
Figure 10. Diagram summarizing proposed mechanism by which MPO induces matrix oxidation and its 
contributions to the generation of vulnerable plaques. Myeloperoxidase (MPO) released by activated leukocytes 
shows a high affinity for matrix proteins, with its catalytic activity remaining unchanged. Matrix-bound MPO 
catalyzes the reaction of H2O2 with Cl− to give HOCl, which subsequently induces oxidation of matrix proteins 
to which MPO is bound or closely associated. The progression of atherosclerosis enhances the concentration of 
H2O2 within the lesion, which facilitates the accumulation of oxidative modifications to the ECM of the lesion, 
increasing the susceptibility of the lesion to further damage and rupture.
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ELISA of ECM materials and modification products. HCASMCs were cultured in 96-well plates at 
an initial density of 1 × 104 cells per well in 200 μL of growth medium (as above) for 1 week to allow synthesis 
of native HCASMC-ECM. The plates were rinsed twice with PBS followed by the incubation with 1% sodium 
deoxycholate (DOC) twice for 10 min at 21 °C. The plates were rinsed 5 times with PBS and the prepared native 
HCASMC-ECM was then treated with 50 μL of HOCl (0–100 μM), or an MPO-H2O2-Cl− system (20 nM MPO, 
0–100 μM H2O2, 200 mM Cl−) at 37 °C for 2 h. Alternatively, a glucose oxidase (GO)-MPO system was used to 
treat HCASMC-ECM. Briefly, the HCASMC-ECM in 96-well plates were prepared as described above and then 
incubated with either 50 μL of GO-MPO system (0–400 mU mL−1 GO and 20 nM MPO) for 20 h at 37 °C, or with 
50 μL of GO-MPO system (400 mU mL−1 GO, 20 nM MPO) for 0–20 h at 37 °C. The plates were rinsed twice 
with PBS followed by blocking with 0.1% (w/v) casein in PBS. Plates were then incubated with the following 
primary antibodies, at the indicated dilutions, at 4 °C overnight: anti-fibronectin pAb (1:1000), anti-versican 
G1 domain mAb (12C5; 1:1000), mouse anti-MPO mAb (2C7, 1:1000) and anti-HOCl generated epitope mAb 
(2D10G9; 1:200). For the experiments using HOCl, the plates were rinsed twice with PBST (0.1% Tween-20 in 
PBS) and incubated with either horseradish peroxidase (HRP)-conjugated sheep anti-mouse or anti-rabbit IgG 
secondary antibodies (1:1000) followed by two more washes with PBST. The plates were subsequently developed 
with 50 mM sodium citrate (pH 4.6) containing 2 mM ABTS [2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic 
acid] and 3 mM H2O2 for 30 min. For the experiments using MPO, the plates were incubated with alkaline 
phosphatase-conjugated rabbit anti-mouse (Abcam) or goat anti-rabbit IgG (Abcam) secondary antibodies at 
21 °C for 1 h, washed twice with PBST then developed with p-nitrophenylphosphate solution (Merck) at 21 °C for 
20 min. The optical absorbance of the resulting chromophores was determined using a Spectra Max i3x microplate 
reader (Molecular Devices). The alkaline phosphatase system was employed for MPO experiments, rather than 
the HRP/ABTS/H2O2 system, as both MPO and HRP react with H2O2, which causes erroneous absorbance data. 
Values for 1% BSA/PBS only wells were used as background to normalize the ELISA readings.
Immunoprecipitation (IP) of MPO-FN protein complexes. MPO (20 nM) was incubated with human 
plasma-derived FN (20 nM) in PBS for 30 min at 37 °C to generate possible MPO-FN complexes. Protein A/G 
magnetic beads (25 μL per IP sample; Pierce, IL, USA) were prepared as per the manufacturer’s instructions, and 
incubated with 2 μg of anti-MPO mAb (2C7) for 1 h at 21 °C on a rotating mixer. The beads were then washed 
twice with the wash buffer provided by manufacturer, and in accordance with the provided instructions, prior 
to incubating with the MPO-FN mixture overnight at 4 °C on the rotating mixer. Negative controls using beads 
only with MPO/anti-MPO mAb (2C7) or MPO-FN complexes alone were also included. Next day, the beads were 
washed twice with wash buffer and once with MilliQ water prior to the addition of 20 μL elution buffer and 2 μL 
of neutralization buffer for 10 min at 21 °C. The eluted samples were transferred to clean tubes and 8.5 μL of 4x 
NuPAGE sample buffer, and 3.4 μL of 10x NuPAGE reducing agent, were added then heat denatured for 5 min at 
90 °C as per the manufacturer’s protocol (Invitrogen, CA, USA). Seventeen μL of sample were loaded per lane, on 
to 3–8% Tris-acetate gels and electrophoresed for 65 min at 160 V. The separated proteins were then transferred 
onto a PVDF membrane using an iBlot 2 system (Invitrogen, CA, USA) for 7 min at 25 V. The membrane was then 
blocked using 1% (w/v) BSA/TBST (0.1% Tween-20) blocking buffer for 1 h, at 21 °C, then incubated for 1 h with 
anti-FN pAb (1:2000 dilution; ab2413; Abcam) on a shaker at 21 °C. The membrane was washed twice with TBST 
prior to incubating with donkey anti-rabbit IgG HRP conjugated (1:5000 dilution) secondary antibody for 1 h at 
21 °C followed by 4 × 15 min TBST washes. The membrane was rinsed twice with TBS and subsequently imaged 
using a Sapphire Azure biomolecular imager (Azure Biosystems, CA, USA) to examine the presence of MPO-FN 
protein complexes immunoprecipitated using anti-MPO mAb (2C7).
Quantification of HOCl production by reaction with taurine and assay with 3,3′,5,5′- 
tetramethylbenzidine (TMB). Decellularized HCASMC-ECM in 96-well plates was prepared as described 
above. The plates were incubated with 50 μL of HOCl (0–100 μM) at 37 °C for 2 h followed by two rinses with PBS. 
Plates were then blocked with 1% BSA/PBS at 21 °C for 1 h and then incubated with 20 nM of MPO at 37 °C for 
30 min. Residual materials were then removed by washing twice with PBS, followed by incubation with 50 μM 
H2O2, 200 mM Cl− and 10 mM taurine at 37 °C for 2 h. The HOCl generated by matrix-bound MPO, and trapped 
with taurine as the corresponding chloramine, was subsequently quantified44 using a developing reagent consist-
ing of 20 mM TMB in dimethylformamide and 2 mM sodium iodide in sodium acetate buffer (0.44 M, pH 5.4). 
This was prepared immediately prior to addition to all samples, with 25 μL added to each well and incubated at 
21 °C for 5 min. The absorbance at 645 nm was subsequently determined using a Spectra Max i3x microplate 
reader (Molecular Devices).
carbonyl assay. The plates for carbonyl detection were prepared as described above for the ELISA experi-
ments. The resulting native HCASMC-ECM was exposed to 50 μL of HOCl (0–200 μM) for 2 h at 37 °C and the 
plates were then rinsed twice with PBS. The carbonyl levels were quantified using an OxyBlot Protein Oxidation 
Detection Kit (S7150, Merck, USA) according to the manufacturer’s instructions with minor modifications. 
Briefly, the ECM on plates were derivatized by incubating with 50 μL of 1 × DNPH for 15 min at 21 °C, then 
rinsed twice with PBS followed by blocking with 0.1% (w/v) casein in PBS. Plates were then incubated with rabbit 
anti-DNP antibody (1:500) at 4 °C overnight, rinsed twice with PBST (0.1% Tween-20 in PBS), incubated with 
horseradish peroxidase (HRP)-conjugated sheep anti-rabbit IgG secondary antibodies (1:1000) for 1 h at 21 °C, 
then washed twice with PBST. The plates were subsequently developed in 50 mM sodium citrate (pH 4.6) buffer 
containing 2 mM ABTS and 3 mM H2O2 for 30 min, with the resulting absorbance at 405 nm measured using a 
Spectra Max i3x microplate reader (Molecular Devices).
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Statistics. All the statistical analyses was performed by one-way ANOVA and post-hoc testing as described in 
the figure legends, using IBM SPSS 19.0. Results are representative of triplicate independent experiments (n = 3) 
with * and ** indicating statistical significance at the p < 0.05 and p < 0.01 levels respectively.
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